07:05 AM EDT, 10/22/2025 (MT Newswires) -- Boston Scientific ( BSX ) reported Q3 adjusted earnings Wednesday of $0.75 per diluted share, up from $0.63 a year earlier.

Analysts polled by FactSet expected $0.71.

Sales for the quarter ended Sept. 30 were $5.07 billion, up from $4.21 billion a year earlier.

Analysts surveyed by FactSet expected $4.97.

For Q4, the biotech firm said it expects adjusted EPS of $0.77 to $0.79 on sales growth of 14.5% to 16.5%. Analysts polled by FactSet expect non-GAAP EPS of $0.76.

For 2025, the company lifted its guidance to adjusted EPS of between $3.02 and $3.04 on sales growth of around 20%, up from its previous guidance of $2.95 to $2.99 adjusted EPS on sales growth of 18% to 19%. Analysts polled by FactSet expect non-GAAP EPS of $2.98.

Shares of the company were down 1.4% in recent Wednesday premarket activity.